Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration
Nurix Therapeutics, Inc. (NRIX) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript